04 September 2026

---

Dentsply Sirona Reports Strong PrimeTaper EV Results

---

A multicenter post-market clinical study conducted across five international centers demonstrated 98.5% implant survival, progressive increases in implant stability, and minimal marginal bone level changes with the PrimeTaper EV implant system.

Dentsply Sirona announces the results of a new multicenter, prospective, post-market clinical study¹ evaluating the one-year performance of the PrimeTaper EV implant system. Conducted across five centers in Belgium, the Netherlands, Italy, the United States, and Germany, the open-label, single-arm study followed 136 patients from implant placement through permanent restoration and one year of follow-up after permanent restoration.

The study assessed implant survival, stability (measured by insertion torque and resonance frequency analysis), marginal bone level changes, and safety. One year after permanent restoration, implant survival was 98.5% (134 of 136 implants), with an implant success rate of 95.6%. Machine-driven insertions, representing 94.9% of cases, achieved a mean final insertion torque of 31.2 ± 12.7 Ncm. Implant stability, measured by ISQ, increased from 71.8 ± 11.2 at placement to 79.3 ± 6.9 at permanent restoration. Mean marginal bone level changes were minimal, at -0.16 ± 0.51 mm from placement to one-year post-restoration. No serious adverse device effects were reported during the study period.

“For four decades, Dentsply Sirona has invested in clinical research to ensure that innovation is supported by scientific evidence. These encouraging one-year results demonstrate that the PrimeTaper EV Implant System supports clinicians in delivering predictable performance with excellent survival rates, progressive stability, and minimal marginal bone changes. They further reinforce our commitment to developing solutions that help clinicians achieve predictable treatment outcomes for their patients,” said Rainer Seemann, Vice President and Chief Clinical Officer at Dentsply Sirona.

A Continued Commitment to Scientific Research

The study’s findings further strengthened Dentsply Sirona’s long-standing commitment to evidence-based dentistry and continuous scientific research. The company’s implant portfolio is supported by an extensive body of scientific evidence and clinical publications. Since launching its Company Initiated Study program in 1985, Dentsply Sirona has conducted 64 clinical studies, contributing to a scientific foundation that spans four decades of research and includes outcomes from the first generation of Dentsply Sirona implants, first published in 1992.

Beyond its own research program, Dentsply Sirona supports independent research through its Investigator Initiated Studies (IIS) Program, which helps fund and facilitate clinical, case series, in vitro, and mechanical studies led by clinicians and universities worldwide. Between 2003 and 2025, the program received 1,146 study proposals from investigators in 45 countries. Today, the IIS program supports more than 170 active studies involving over 140 investigators across more than 25 countries.

Together, these programs contribute to Dentsply Sirona’s broader scientific footprint, which includes more than 3,000 peer-reviewed publications involving products across its implant and prosthetic portfolio, as well as data from over 40,000 documented patients and 125,000 documented implants.

Dentsply Sirona Implants Publication List, available at Implants Science | Dentsply Sirona USA .

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective, and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY.

Source: https://link.mediaoutreach.meltwater.com/ls/click?upn=u001.Jr-2FyrQPF1GAXEIbWypMznVxqDj4XQ8HtLNldIFO6CRfNKc7dNrZDM1SdMU-2FsyODN1Ah2Acv-2BVjIL-2BNKnCNsjlacoXgqQ-2BYkD57gsrxtPPihOLEhg17x0AT5WjgstWUPoIn4hdkeAW56VgZR7STHTGeXGOVVOiet5WjrymFXInus-3D-N0L_tNflRwz0Orjc2YD7-2F7KAPxX26FQdB6ClUXWi7o6J3xckXe7Uz-2Fnm-2B8m8GP5ATopBonBDzu0Z-2BhaJ5bIYqJ0yWOaP-2FjCWUQFOtzdvotxF8e-2FJfWogSGDFEVZVQZU73rN5QQA-2FJC981vO-2F6ycCx8P7-2Fmg6eKG56Mz0npXZ-2BGY6jW-2FdcnWGKk12hqf2flPHKY-2BxsmoZXORqbi8fb-2B3daoRmrWqLFE0kW8EdO2jMl58yO1V3PPUFdEPU8vXZM8tuosRf4nGQiOsjU4e4QFGwXHkCfkFKWmEhRWOz-2FHNhrppWrkurtwrjEJxcNzeW3lx53MqWNTu0q6mg44oUVvuWrEpPd5lZuTTRhMT3eDYk14orM2oQoZczItoyjhcSafOX7T0iOoqf9A8M9lPVJQBLMgbgSg-3D-3D